GLP‐1R agonist agents (e.g., exenatide, lixisenatide, liraglutide, semaglutide, etc.)lower glucose levels and reduce cognitive deficits observed in T2DM (Aroda, 2018; Gomez‐Peralta & Abreu, 2019; Grieco et al., 2019). Here, GLP1R is linked to type 2 diabetes mellitus.